G1 Therapeutics, Inc. (GTHX)
NASDAQ: GTHX · IEX Real-Time Price · USD
3.630
-0.010 (-0.27%)
At close: Jul 19, 2024, 4:00 PM
3.590
-0.040 (-1.10%)
Pre-market: Jul 22, 2024, 8:55 AM EDT
G1 Therapeutics Employees
G1 Therapeutics had 100 employees as of December 31, 2023. The number of employees decreased by 70 or -41.18% compared to the previous year.
Employees
100
Change (1Y)
-70
Growth (1Y)
-41.18%
Revenue / Employee
$840,410
Profits / Employee
-$305,910
Market Cap
189.78M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
EDAP TMS | 307 |
Seres Therapeutics | 233 |
908 Devices | 230 |
Inhibrx | 172 |
OptimizeRx | 136 |
Candel Therapeutics | 42 |
Trevi Therapeutics | 25 |
GTHX News
- 21 days ago - G1 Therapeutics Added to the Russell 2000® and 3000® Indexes - GlobeNewsWire
- 27 days ago - Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? - Benzinga
- 4 weeks ago - G1 Therapeutics' breast cancer drug fails in late-stage trial - Reuters
- 4 weeks ago - G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) - GlobeNewsWire
- 6 weeks ago - G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) - GlobeNewsWire
- 2 months ago - G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting - GlobeNewsWire
- 2 months ago - G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit - GlobeNewsWire